Skip to Main Navigation
Skip to Page Content
Share This:
https://ntp.niehs.nih.gov/go/12584

TDMS Study 05203-09 Pathology Tables

NTP Experiment-Test: 05203-09  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                           O-NITROTOLUENE                                      Date: 11/30/00
Route: DOSED FEED                                                                                                 Time: 09:09:35

                                                          MICE/FINAL#1




       Facility:  Southern Research Institute

       Chemical CAS #:  88-72-2

       Lock Date:  03/08/99

       Cage Range:  All

       Reasons For Removal:    All

       Removal Date Range:     All

       Treatment Groups:       Include All


































a  Number of animals examined microscopically at site and number of animals with lesion

                                                              Page   1


NTP Experiment-Test: 05203-09  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                           O-NITROTOLUENE                                      Date: 11/30/00  
Route: DOSED FEED                                                                                                 Time: 09:09:35  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE FEMALE                        0 PPM        1250 PPM     2500 PPM     5000 PPM                                  
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
DISPOSITION SUMMARY                                                                                                                 
                                                                                                                                    
  Animals Initially in Study                          60           60           60           60                                     
  Early Deaths                                                                                                                      
    Moribund Sacrifice                                 4            6            7           22                                     
    Natural Death                                      4            8            6           33                                     
  Survivors                                                                                                                         
    Terminal Sacrifice                                52           46           47            5                                     
                                                                                                                                    
  Animals Examined Microscopically                    60           60           60           60                                     
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   Esophagus                                          (60)         (60)         (59)         (57)                                   
   Gallbladder                                        (54)         (53)         (54)         (31)                                   
   Intestine Large, Colon                             (56)         (55)         (57)         (41)                                   
      Hemangiosarcoma, Metastatic, Mesentery                                                  1 (2%)                                
   Intestine Large, Cecum                             (56)         (53)         (54)         (32)                                   
      Carcinoma                                                     1 (2%)       4 (7%)       3 (9%)                                
      Sarcoma                                                                    1 (2%)                                             
   Intestine Small, Jejunum                           (56)         (53)         (56)         (34)                                   
      Carcinoma                                                                               1 (3%)                                
   Intestine Small, Ileum                             (57)         (53)         (56)         (34)                                   
   Liver                                              (60)         (59)         (59)         (60)                                   
      Cholangioma                                                                             1 (2%)                                
      Hemangiosarcoma                                                            1 (2%)                                             
      Hemangiosarcoma, Metastatic, Skin                                                       1 (2%)                                
      Hepatocellular Carcinoma                         2 (3%)       3 (5%)       4 (7%)       9 (15%)                               
      Hepatocellular Carcinoma, Multiple                            1 (2%)       2 (3%)       7 (12%)                               
      Hepatocellular Adenoma                           7 (12%)      5 (8%)      16 (27%)      9 (15%)                               
      Hepatocellular Adenoma, Multiple                                           3 (5%)      20 (33%)                               
      Hepatocholangiocarcinoma                                                                1 (2%)                                
      Histiocytic Sarcoma                                           2 (3%)       1 (2%)                                             
      Osteosarcoma, Metastatic, Bone                                1 (2%)                                                          
      Sarcoma, Metastatic, Uncertain Primary Site                                1 (2%)                                             
   Mesentery                                          (11)         (9)          (9)          (34)                                   
      Carcinoma, Metastatic, Uncertain Primary Site                 1 (11%)                                                         
      Carcinoma, Metastatic, Intestine Large, Cecum                              1 (11%)                                            
      Hemangiosarcoma                                                                        25 (74%)                               
      Hemangiosarcoma, Multiple                                                               7 (21%)                               
      Histiocytic Sarcoma                                           1 (11%)                                                         
      Sarcoma                                                                                 1 (3%)                                
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   2                                                               
                                                                                                                                   
NTP Experiment-Test: 05203-09  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                           O-NITROTOLUENE                                      Date: 11/30/00  
Route: DOSED FEED                                                                                                 Time: 09:09:35  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE FEMALE                        0 PPM        1250 PPM     2500 PPM     5000 PPM                                  
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
ALIMENTARY SYSTEM - cont                                                                                                            
      Sarcoma, Multiple                                                          1 (11%)                                            
      Sarcoma, Metastatic, Skin                                                  1 (11%)                                            
      Sarcoma, Metastatic, Skeletal Muscle                                       1 (11%)                                            
   Pancreas                                           (60)         (57)         (58)         (57)                                   
      Hemangiosarcoma, Metastatic, Mesentery                                                  1 (2%)                                
      Sarcoma                                                                    1 (2%)                                             
      Sarcoma, Metastatic, Mesentery                                                          1 (2%)                                
   Salivary Glands                                    (59)         (59)         (58)         (49)                                   
      Histiocytic Sarcoma                                                        1 (2%)                                             
   Stomach, Forestomach                               (60)         (58)         (58)         (59)                                   
      Hemangioma                                       1 (2%)                                                                       
      Squamous Cell Papilloma                          1 (2%)       2 (3%)       2 (3%)       1 (2%)                                
   Stomach, Glandular                                 (58)         (57)         (57)         (52)                                   
      Sarcoma                                                                    1 (2%)                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   Heart                                              (60)         (60)         (59)         (58)                                   
      Carcinoma, Metastatic, Uncertain Primary Site                 1 (2%)                                                          
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   Adrenal Cortex                                     (59)         (59)         (58)         (60)                                   
      Capsule, Adenoma                                 1 (2%)                                                                       
   Adrenal Medulla                                    (59)         (57)         (58)         (59)                                   
      Pheochromocytoma Benign                                       1 (2%)                                                          
   Islets, Pancreatic                                 (60)         (57)         (60)         (56)                                   
      Carcinoma                                                     1 (2%)                                                          
   Pituitary Gland                                    (58)         (58)         (53)         (53)                                   
      Adenoma                                          1 (2%)                                                                       
      Pars Distalis, Adenoma                           2 (3%)       4 (7%)       3 (6%)                                             
      Pars Intermedia, Adenoma                                                   1 (2%)                                             
   Thyroid Gland                                      (60)         (59)         (58)         (53)                                   
      Follicular Cell, Adenoma                                      1 (2%)                                                          
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   3                                                               
                                                                                                                                   
NTP Experiment-Test: 05203-09  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                           O-NITROTOLUENE                                      Date: 11/30/00  
Route: DOSED FEED                                                                                                 Time: 09:09:35  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE FEMALE                        0 PPM        1250 PPM     2500 PPM     5000 PPM                                  
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   Tissue NOS                                         (1)                       (3)          (3)                                    
      Abdominal, Hemangiosarcoma                                                              1 (33%)                               
      Abdominal, Hemangiosarcoma, Multiple                                                    1 (33%)                               
      Thoracic, Sarcoma                                                                       1 (33%)                               
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   Ovary                                              (59)         (56)         (56)         (56)                                   
      Carcinoma                                                     1 (2%)                                                          
      Cystadenoma                                      1 (2%)                    2 (4%)                                             
      Hemangiosarcoma                                               1 (2%)                                                          
      Histiocytic Sarcoma                                           1 (2%)                                                          
      Luteoma                                          2 (3%)                    1 (2%)       1 (2%)                                
      Teratoma Malignant                                                         1 (2%)                                             
      Tubulostromal Adenoma                                         1 (2%)                                                          
   Oviduct                                            (1)                                                                           
   Uterus                                             (60)         (59)         (60)         (59)                                   
      Hemangioma                                       1 (2%)       2 (3%)                                                          
      Hemangiosarcoma                                               1 (2%)                    2 (3%)                                
      Histiocytic Sarcoma                                           1 (2%)       1 (2%)                                             
      Leiomyoma                                                     1 (2%)                                                          
      Leiomyosarcoma                                                             1 (2%)                                             
      Cervix, Hemangiosarcoma                                                                 1 (2%)                                
      Endometrium, Carcinoma                                                     1 (2%)                                             
      Endometrium, Polyp Stromal                       2 (3%)       2 (3%)       2 (3%)                                             
   Vagina                                                          (1)                                                              
      Carcinoma, Metastatic, Uncertain Primary Site                 1 (100%)                                                        
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   Bone Marrow                                        (60)         (58)         (60)         (60)                                   
      Carcinoma, Metastatic, Uncertain Primary Site                 1 (2%)                                                          
      Histiocytic Sarcoma                                           1 (2%)       1 (2%)                                             
   Lymph Node                                         (6)          (3)          (10)         (11)                                   
      Iliac, Sarcoma, Metastatic, Skin                                                        1 (9%)                                
      Inguinal, Sarcoma, Metastatic, Skin                                        1 (10%)                                            
      Mediastinal, Sarcoma, Metastatic, Uncertain                                                                                   
          Primary Site                                                                        1 (9%)                                
      Pancreatic, Sarcoma                                                        1 (10%)                                            
      Renal, Hemangiosarcoma, Metastatic, Mesentery                                           1 (9%)                                
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   4                                                               
                                                                                                                                   
NTP Experiment-Test: 05203-09  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                           O-NITROTOLUENE                                      Date: 11/30/00  
Route: DOSED FEED                                                                                                 Time: 09:09:35  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE FEMALE                        0 PPM        1250 PPM     2500 PPM     5000 PPM                                  
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
HEMATOPOIETIC SYSTEM - cont                                                                                                         
      Renal, Sarcoma, Metastatic, Skin                                           1 (10%)      1 (9%)                                
   Lymph Node, Mandibular                             (58)         (55)         (55)         (48)                                   
      Histiocytic Sarcoma                                                        1 (2%)                                             
   Lymph Node, Mesenteric                             (53)         (58)         (57)         (57)                                   
      Histiocytic Sarcoma                                           1 (2%)       1 (2%)                                             
      Sarcoma                                          1 (2%)                                                                       
      Sarcoma, Metastatic, Mesentery                                                          1 (2%)                                
   Spleen                                             (59)         (57)         (58)         (57)                                   
      Histiocytic Sarcoma                                                        1 (2%)                                             
   Thymus                                             (57)         (56)         (55)         (44)                                   
      Thymoma Malignant                                                          1 (2%)                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   Skin                                               (60)         (60)         (60)         (60)                                   
      Basal Cell Carcinoma                                                                    1 (2%)                                
      Basosquamous Tumor Malignant                                  1 (2%)                                                          
      Subcutaneous Tissue, Carcinoma, Multiple                      1 (2%)                                                          
      Subcutaneous Tissue, Hemangiosarcoma                                       2 (3%)      16 (27%)                               
      Subcutaneous Tissue, Hemangiosarcoma,                                                                                         
          Multiple                                                                            3 (5%)                                
      Subcutaneous Tissue, Sarcoma                     1 (2%)       1 (2%)       5 (8%)       2 (3%)                                
      Subcutaneous Tissue, Sarcoma, Multiple                                     1 (2%)                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   Bone                                               (60)         (60)         (60)         (60)                                   
      Osteosarcoma                                                  1 (2%)                                                          
      Femur, Osteosarcoma                                                        1 (2%)                                             
   Skeletal Muscle                                    (2)          (3)          (3)          (18)                                   
      Carcinoma, Metastatic, Uncertain Primary Site                 1 (33%)                                                         
      Hemangioma                                       1 (50%)                                                                      
      Hemangiosarcoma                                                                        14 (78%)                               
      Hemangiosarcoma, Multiple                                                               2 (11%)                               
      Sarcoma                                                       1 (33%)      2 (67%)      1 (6%)                                
      Sarcoma, Multiple                                                          1 (33%)      1 (6%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   5                                                               
                                                                                                                                   
NTP Experiment-Test: 05203-09  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                           O-NITROTOLUENE                                      Date: 11/30/00  
Route: DOSED FEED                                                                                                 Time: 09:09:35  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE FEMALE                        0 PPM        1250 PPM     2500 PPM     5000 PPM                                  
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   Lung                                               (60)         (60)         (59)         (57)                                   
      Alveolar/Bronchiolar Adenoma                     2 (3%)       3 (5%)       4 (7%)       4 (7%)                                
      Alveolar/Bronchiolar Carcinoma                   3 (5%)       1 (2%)                                                          
      Alveolar/Bronchiolar Carcinoma, Multiple                      2 (3%)                    2 (4%)                                
      Carcinoma, Metastatic, Harderian Gland                        1 (2%)                    1 (2%)                                
      Carcinoma, Metastatic, Uncertain Primary Site                 1 (2%)                                                          
      Hemangiosarcoma, Metastatic, Skin                                                       1 (2%)                                
      Hemangiosarcoma, Metastatic, Uncertain                                                                                        
          Primary Site                                                                        1 (2%)                                
      Hemangiosarcoma, Metastatic, Skeletal Muscle                                            2 (4%)                                
      Hepatocellular Carcinoma, Metastatic, Liver                   1 (2%)                    1 (2%)                                
      Histiocytic Sarcoma                                           1 (2%)       1 (2%)                                             
      Osteosarcoma, Metastatic, Bone                                1 (2%)       1 (2%)                                             
      Sarcoma, Metastatic, Mesentery                                                          1 (2%)                                
      Sarcoma, Metastatic, Skeletal Muscle                                       1 (2%)                                             
      Teratoma Malignant, Metastatic, Ovary                                      1 (2%)                                             
      Mediastinum, Alveolar/Bronchiolar Carcinoma,                                                                                  
           Metastatic, Lung                                         1 (2%)                                                          
      Mediastinum, Carcinoma                                        1 (2%)                                                          
      Mediastinum, Carcinoma, Metastatic,                                                                                           
          Harderian Gland                                           1 (2%)                                                          
      Mediastinum, Histiocytic Sarcoma                                           1 (2%)                                             
      Mediastinum, Sarcoma, Metastatic, Uncertain                                                                                   
          Primary Site                                                           1 (2%)                                             
      Mediastinum, Sarcoma, Metastatic, Skeletal                                                                                    
          Muscle                                                                 1 (2%)                                             
   Nose                                               (60)         (60)         (59)         (57)                                   
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   Harderian Gland                                    (5)          (1)          (4)          (4)                                    
      Adenoma                                          4 (80%)                   1 (25%)      2 (50%)                               
      Carcinoma                                        1 (20%)      1 (100%)     3 (75%)      2 (50%)                               
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   6                                                               
                                                                                                                                   
NTP Experiment-Test: 05203-09  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                           O-NITROTOLUENE                                      Date: 11/30/00  
Route: DOSED FEED                                                                                                 Time: 09:09:35  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE FEMALE                        0 PPM        1250 PPM     2500 PPM     5000 PPM                                  
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   Kidney                                             (59)         (56)         (58)         (59)                                   
      Carcinoma                                                     1 (2%)                                                          
      Histiocytic Sarcoma                                           1 (2%)                                                          
   Urinary Bladder                                    (59)         (54)         (57)         (54)                                   
      Hemangiosarcoma                                                                         1 (2%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SYSTEMIC LESIONS                                                                                                                   
                                                                                                                                    
   Multiple Organs                                   *(60)        *(60)        *(60)        *(60)                                   
      Histiocytic Sarcoma                                           2 (3%)       1 (2%)                                             
      Lymphoma Malignant                               8 (13%)      7 (12%)      5 (8%)       3 (5%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
     *   Number of animals with any tissue examined microscopically                                                                 
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   7                                                               
                                                                                                                                   
NTP Experiment-Test: 05203-09  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                           O-NITROTOLUENE                                      Date: 11/30/00  
Route: DOSED FEED                                                                                                 Time: 09:09:35  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE FEMALE                        0 PPM        1250 PPM     2500 PPM     5000 PPM                                  
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
TUMOR SUMMARY                                                                                                                       
                                                                                                                                    
   Total Animals with Primary Neoplasms (b)            33          37          44          56                                       
     Total Primary Neoplasms                           42          51          76         146                                       
                                                                                                                                    
   Total Animals with Benign Neoplasms                 21          20          26          33                                       
     Total Benign Neoplasms                            26          22          35          38                                       
                                                                                                                                    
   Total Animals with Malignant Neoplasms              16          23          27          55                                       
     Total Malignant Neoplasms                         16          29          41         108                                       
                                                                                                                                    
   Total Animals with Metastatic Neoplasms                          4           6          12                                       
     Total Metastatic Neoplasm                                     12          11          16                                       
                                                                                                                                    
   Total Animals with Malignant Neoplasms                           1           1           2                                       
   Uncertain Primary Site                                                                                                           
                                                                                                                                    
   Total Animals with Neoplasms Uncertain-                                                                                          
   Benign or Malignant                                                                                                              
     Total Uncertain Neoplasms                                                                                                      
                                                                                                                                    
                                                                                                                                    
____________________________________________________________________________________________________________________________________
a  Number of animals examined microscopically at site and number of animals with lesion                                             
b  Primary tumors: all tumors except metastatic tumors                                                                              
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   8                                                               
                                                                                                                                   
NTP Experiment-Test: 05203-09  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                           O-NITROTOLUENE                                      Date: 11/30/00  
Route: DOSED FEED                                                                                                 Time: 09:09:35  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE MALE                          0 PPM        1250 PPM     2500 PPM     5000 PPM                                  
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
DISPOSITION SUMMARY                                                                                                                 
                                                                                                                                    
  Animals Initially in Study                          60           60           60           60                                     
  Early Deaths                                                                                                                      
    Natural Death                                      5           21           39           29                                     
    Moribund Sacrifice                                 3            5           21           31                                     
  Survivors                                                                                                                         
    Terminal Sacrifice                                52           34                                                               
                                                                                                                                    
  Animals Examined Microscopically                    60           60           60           60                                     
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   Gallbladder                                        (54)         (42)         (31)         (35)                                   
   Intestine Large, Colon                             (56)         (52)         (46)         (54)                                   
      Muscularis, Serosa, Hemangiosarcoma                                        1 (2%)                                             
   Intestine Large, Cecum                             (56)         (49)         (36)         (44)                                   
      Carcinoma                                                    12 (24%)      9 (25%)                                            
   Intestine Small, Duodenum                          (55)         (45)         (40)         (42)                                   
      Hemangiosarcoma                                  1 (2%)                                                                       
   Intestine Small, Jejunum                           (56)         (43)         (35)         (40)                                   
      Adenocarcinoma                                   1 (2%)                                                                       
      Carcinoma                                        1 (2%)                                                                       
   Intestine Small, Ileum                             (55)         (40)         (35)         (39)                                   
      Carcinoma                                                     1 (3%)                                                          
   Liver                                              (60)         (59)         (57)         (60)                                   
      Hemangiosarcoma                                  1 (2%)       1 (2%)       1 (2%)                                             
      Hemangiosarcoma, Multiple                                     3 (5%)                                                          
      Hemangiosarcoma, Metastatic, Skeletal Muscle                               1 (2%)                                             
      Hepatoblastoma                                   1 (2%)       1 (2%)                                                          
      Hepatocellular Carcinoma                         9 (15%)      9 (15%)      4 (7%)       2 (3%)                                
      Hepatocellular Carcinoma, Multiple               3 (5%)       7 (12%)      1 (2%)                                             
      Hepatocellular Adenoma                          15 (25%)     12 (20%)      1 (2%)                                             
      Hepatocellular Adenoma, Multiple                 3 (5%)       6 (10%)      2 (4%)                                             
      Histiocytic Sarcoma                                           1 (2%)                                                          
   Mesentery                                          (12)         (12)         (42)         (38)                                   
      Carcinoma, Metastatic, Intestine Large, Cecum                 1 (8%)       1 (2%)                                             
      Hemangiosarcoma                                               8 (67%)     30 (71%)     24 (63%)                               
      Hemangiosarcoma, Multiple                                                  8 (19%)     14 (37%)                               
      Hemangiosarcoma, Metastatic, Skeletal Muscle                               1 (2%)                                             
   Oral Mucosa                                                     (1)                                                              
      Pharyngeal, Squamous Cell Carcinoma                           1 (100%)                                                        
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   9                                                               
                                                                                                                                   
NTP Experiment-Test: 05203-09  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                           O-NITROTOLUENE                                      Date: 11/30/00  
Route: DOSED FEED                                                                                                 Time: 09:09:35  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE MALE                          0 PPM        1250 PPM     2500 PPM     5000 PPM                                  
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
ALIMENTARY SYSTEM - cont                                                                                                            
   Pancreas                                           (59)         (59)         (59)         (58)                                   
      Hemangiosarcoma                                                                         1 (2%)                                
      Acinus, Hemangiosarcoma                                                    1 (2%)                                             
   Salivary Glands                                    (60)         (60)         (60)         (60)                                   
   Stomach, Forestomach                               (60)         (60)         (58)         (60)                                   
      Squamous Cell Papilloma                                                                 2 (3%)                                
   Stomach, Glandular                                 (57)         (54)         (53)         (55)                                   
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   Heart                                              (60)         (60)         (60)         (60)                                   
      Hemangiosarcoma                                               2 (3%)                    2 (3%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   Adrenal Cortex                                     (60)         (60)         (58)         (60)                                   
      Adenoma                                          1 (2%)                                                                       
      Capsule, Adenoma                                 1 (2%)                                                                       
   Pituitary Gland                                    (53)         (50)         (50)         (46)                                   
      Pars Distalis, Adenoma                           1 (2%)                                                                       
   Thyroid Gland                                      (59)         (59)         (59)         (59)                                   
      C-Cell, Carcinoma                                             1 (2%)                                                          
      Follicular Cell, Adenoma                         1 (2%)                                                                       
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   Tissue NOS                                         (2)                       (2)          (3)                                    
      Hemangiosarcoma                                                                         1 (33%)                               
      Pelvic, Hemangiosarcoma                                                    1 (50%)      1 (33%)                               
      Thoracic, Sarcoma                                1 (50%)                                                                      
      Thoracic, Sarcoma, Multiple                      1 (50%)                                                                      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   Coagulating Gland                                                            (2)          (1)                                    
      Hemangiosarcoma                                                            1 (50%)                                            
   Preputial Gland                                    (60)         (59)         (59)         (60)                                   
      Histiocytic Sarcoma                              1 (2%)                                                                       
   Prostate                                           (60)         (59)         (57)         (58)                                   
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page  10                                                               
                                                                                                                                   
NTP Experiment-Test: 05203-09  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                           O-NITROTOLUENE                                      Date: 11/30/00  
Route: DOSED FEED                                                                                                 Time: 09:09:35  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE MALE                          0 PPM        1250 PPM     2500 PPM     5000 PPM                                  
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
GENITAL SYSTEM - cont                                                                                                               
      Hemangiosarcoma                                                            4 (7%)                                             
      Hemangiosarcoma, Metastatic, Mesentery                                                  1 (2%)                                
   Testes                                             (60)         (60)         (60)         (60)                                   
      Interstitial Cell, Adenoma                                    1 (2%)                                                          
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   Bone Marrow                                        (60)         (60)         (60)         (60)                                   
      Hemangiosarcoma                                               1 (2%)                                                          
      Mast Cell Tumor Malignant                        1 (2%)                                                                       
   Lymph Node                                         (3)          (4)          (7)          (1)                                    
      Inguinal, Hemangiosarcoma, Metastatic,                                                                                        
          Skeletal Muscle                                                                     1 (100%)                              
      Mediastinal, Hemangiosarcoma, Metastatic,                                                                                     
           Mesentery                                                             1 (14%)                                            
      Mediastinal, Sarcoma, Metastatic, Tissue NOS     1 (33%)                                                                      
      Pancreatic, Histiocytic Sarcoma                               1 (25%)                                                         
   Lymph Node, Mandibular                             (59)         (55)         (50)         (54)                                   
      Hemangioma                                                                 1 (2%)                                             
   Lymph Node, Mesenteric                             (60)         (55)         (56)         (53)                                   
      Carcinoma, Metastatic, Intestine Large, Cecum                 1 (2%)       3 (5%)                                             
      Hemangiosarcoma, Metastatic, Spleen              1 (2%)                                                                       
      Histiocytic Sarcoma                                           1 (2%)                                                          
   Spleen                                             (60)         (60)         (58)         (60)                                   
      Hemangioma                                       1 (2%)                                                                       
      Hemangiosarcoma                                  2 (3%)       3 (5%)                                                          
      Histiocytic Sarcoma                                           1 (2%)                                                          
   Thymus                                             (57)         (52)         (45)         (54)                                   
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   Skin                                               (60)         (60)         (60)         (60)                                   
      Sebaceous Gland, Carcinoma                                    1 (2%)                                                          
      Subcutaneous Tissue, Fibrosarcoma                                          1 (2%)                                             
      Subcutaneous Tissue, Hemangioma                               1 (2%)                                                          
      Subcutaneous Tissue, Hemangiosarcoma                          4 (7%)       8 (13%)     12 (20%)                               
      Subcutaneous Tissue, Hemangiosarcoma,                                                                                         
          Multiple                                                                            8 (13%)                               
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page  11                                                               
                                                                                                                                   
NTP Experiment-Test: 05203-09  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                           O-NITROTOLUENE                                      Date: 11/30/00  
Route: DOSED FEED                                                                                                 Time: 09:09:35  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE MALE                          0 PPM        1250 PPM     2500 PPM     5000 PPM                                  
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   Bone                                               (60)         (60)         (60)         (60)                                   
      Cranium, Osteoma                                              1 (2%)                                                          
   Skeletal Muscle                                    (1)          (6)          (35)         (47)                                   
      Hemangiosarcoma                                               6 (100%)    25 (71%)     19 (40%)                               
      Hemangiosarcoma, Multiple                                                  8 (23%)     26 (55%)                               
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   Brain                                              (60)         (60)         (60)         (60)                                   
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   Lung                                               (60)         (60)         (60)         (60)                                   
      Alveolar/Bronchiolar Adenoma                     9 (15%)      6 (10%)      4 (7%)                                             
      Alveolar/Bronchiolar Carcinoma                   3 (5%)       1 (2%)       2 (3%)                                             
      Alveolar/Bronchiolar Carcinoma, Multiple         2 (3%)                                                                       
      Carcinoma, Metastatic, Intestine Large, Cecum                 1 (2%)                                                          
      Hemangiosarcoma, Metastatic, Mesentery                                     3 (5%)       1 (2%)                                
      Hemangiosarcoma, Metastatic, Skin                                          3 (5%)       4 (7%)                                
      Hemangiosarcoma, Metastatic, Uncertain                                                                                        
          Primary Site                                              1 (2%)       1 (2%)       2 (3%)                                
      Hemangiosarcoma, Metastatic, Skeletal Muscle                               2 (3%)       8 (13%)                               
      Hepatocellular Carcinoma, Metastatic, Liver                   2 (3%)       1 (2%)                                             
      Histiocytic Sarcoma                                           1 (2%)                                                          
      Mediastinum, Hemangiosarcoma                                                            4 (7%)                                
   Nose                                               (60)         (60)         (60)         (60)                                   
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   Ear                                                (1)                                                                           
      External Ear, Neural Crest Tumor, Malignant      1 (100%)                                                                     
   Harderian Gland                                    (5)          (3)          (3)                                                 
      Adenoma                                          4 (80%)      1 (33%)      1 (33%)                                            
      Carcinoma                                        1 (20%)      1 (33%)      1 (33%)                                            
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page  12                                                               
                                                                                                                                   
NTP Experiment-Test: 05203-09  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                           O-NITROTOLUENE                                      Date: 11/30/00  
Route: DOSED FEED                                                                                                 Time: 09:09:35  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE MALE                          0 PPM        1250 PPM     2500 PPM     5000 PPM                                  
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   Kidney                                             (58)         (59)         (58)         (60)                                   
      Hemangiosarcoma, Metastatic, Mesentery                                     1 (2%)                                             
      Histiocytic Sarcoma                                           1 (2%)                                                          
      Capsule, Hemangiosarcoma                                                                1 (2%)                                
   Urinary Bladder                                    (59)         (59)         (59)         (60)                                   
      Hemangiosarcoma                                                            1 (2%)                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SYSTEMIC LESIONS                                                                                                                   
                                                                                                                                    
   Multiple Organs                                   *(60)        *(60)        *(60)        *(60)                                   
      Histiocytic Sarcoma                              1 (2%)       1 (2%)                                                          
      Lymphoma Malignant                               3 (5%)                    1 (2%)                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
     *   Number of animals with any tissue examined microscopically                                                                 
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page  13                                                               
                                                                                                                                   
NTP Experiment-Test: 05203-09  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                           O-NITROTOLUENE                                      Date: 11/30/00  
Route: DOSED FEED                                                                                                 Time: 09:09:35  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE MALE                          0 PPM        1250 PPM     2500 PPM     5000 PPM                                  
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
TUMOR SUMMARY                                                                                                                       
                                                                                                                                    
   Total Animals with Primary Neoplasms (b)            45          50          59          60                                       
     Total Primary Neoplasms                           69          92         117         117                                       
                                                                                                                                    
   Total Animals with Benign Neoplasms                 30          24           8           2                                       
     Total Benign Neoplasms                            36          28           9           2                                       
                                                                                                                                    
   Total Animals with Malignant Neoplasms              26          41          59          60                                       
     Total Malignant Neoplasms                         33          64         108         115                                       
                                                                                                                                    
   Total Animals with Metastatic Neoplasms              1           5          13          17                                       
     Total Metastatic Neoplasm                          2           6          18          17                                       
                                                                                                                                    
   Total Animals with Malignant Neoplasms                           1           1           2                                       
   Uncertain Primary Site                                                                                                           
                                                                                                                                    
   Total Animals with Neoplasms Uncertain-                                                                                          
   Benign or Malignant                                                                                                              
     Total Uncertain Neoplasms                                                                                                      
                                                                                                                                    
                                                                                                                                    
____________________________________________________________________________________________________________________________________
a  Number of animals examined microscopically at site and number of animals with lesion                                             
b  Primary tumors: all tumors except metastatic tumors                                                                              
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page  14                                                               
                                                                                                                                   
                             ------------------------------------------------------------                                           
                             ----------              END OF REPORT             ----------                                           
                             ------------------------------------------------------------